Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- HEALTHCARE FORUM
December 12, 2005
- BUSINESS NEWS IN BRIEF
December 12, 2005
- Councilor Calls For Medical, Nursing Fees that Promote Home Care
December 12, 2005
- Korosho Proposes Simplification of Dispensing Fees
December 12, 2005
- 4 Industry Groups Present Their Views at Chuikyo
December 12, 2005
- Chuikyo Makes No Recommendation on Medical Fee Revision
December 12, 2005
- Decision on Pricing of Long-listed Products in Limbo Until Year-end
December 12, 2005
- Korosho to Deal with NHI Drug Prices before Medical Fees: Mr Kawasaki
December 12, 2005
- Healthcare Reform Framework Announced
December 12, 2005
- UCB Aims at Innovation for Specialists
December 12, 2005
- SELF-MEDICATION NEWS IN BRIEF
December 12, 2005
- Discussions on OTC Drug Marketing to Conclude Soon
December 12, 2005
- Japan Lags Behind in Use of Insulin Pump for Type 1 Diabetics
December 12, 2005
- Breast Cancer Screening Needed in Women in Their 40s: Prof. Ohuchi
December 12, 2005
- SURVEY 2 articles
December 12, 2005
- Saitama Medical School Creates Wound Healing & Regenerative Medicine Center
December 12, 2005
- Dr Takenaka Talks on Pharma Industry 10 Years Back and 10 Ahead
December 12, 2005
- MEDICAL DEVICE NEWS IN BRIE
December 12, 2005
- 23 TSE-listed Drug Firms' Sales Up 2.7% to \2,764,792 Mil.
December 12, 2005
- R&D NEWS IN BRIEF
December 12, 2005
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…